Abstract
Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Immunology |
| Volume | 32 |
| Issue number | SUPPL. 2 |
| DOIs | |
| State | Published - Jul 19 2012 |
Fingerprint
Keywords
- AAAAI IGIV toolkit
- Immune Deficiency Foundation
- Jeffrey Modell Foundation
- Primary immunodeficiency disease
- Treatment guidelines
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Local and national advocacy support. / Shapiro, Ralph S.; Boyle, Marcia; Perez, Elena E.
In: Journal of Clinical Immunology, Vol. 32, No. SUPPL. 2, 19.07.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Local and national advocacy support
AU - Shapiro, Ralph S.
AU - Boyle, Marcia
AU - Perez, Elena E.
PY - 2012/7/19
Y1 - 2012/7/19
N2 - Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.
AB - Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.
KW - AAAAI IGIV toolkit
KW - Immune Deficiency Foundation
KW - Jeffrey Modell Foundation
KW - Primary immunodeficiency disease
KW - Treatment guidelines
UR - http://www.scopus.com/inward/record.url?scp=84874403891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874403891&partnerID=8YFLogxK
U2 - 10.1007/s10875-012-9736-6
DO - 10.1007/s10875-012-9736-6
M3 - Article
VL - 32
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
SN - 0271-9142
IS - SUPPL. 2
ER -